Shah Rajeev M. — SEC Form 4 filings
SEC reporting owner CIK 1619841. 158 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers the 50 most recent of 158 filings on record, filed 2026-04-23 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 44 legs across 17 filings — 33,046,427 shares, $578,833,175 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 24 legs across 7 filings — 3,767,503 shares, $67,025,056 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 56.
- Largest priced transaction: purchase of 19,728,353 shares @ $20.00 ($394,567,060) in Parabilis Medicines, Inc., filed 2026-06-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | Director, 10% owner | 3 | 8 legs · 21,433,343 sh · $430,694,551 | — | 7 |
| Artiva Biotherapeutics, Inc. (ARTV) | Director, 10% owner | 12 | 20 legs · 8,642,543 sh · $92,678,453 | — | 3 |
| Septerna, Inc. (SEPN) | Director, 10% owner | 2 | — | 2 legs · 1,493,000 sh · $63,452,500 | 1 |
| Hemab Therapeutics Holdings, Inc. (COAG) | 10% owner | 5 | 16 legs · 2,970,541 sh · $55,460,171 | — | 9 |
| Vor Biopharma Inc. (VOR) | 10% owner | 4 | — | 2 legs · 165,363 sh · $2,608,622 | 5 |
| Werewolf Therapeutics, Inc. (HOWL) | 10% owner | 4 | — | 20 legs · 2,109,140 sh · $963,934 | — |
| Freenome, Inc. (FRNM) | Director, 10% owner | 1 | — | — | 7 |
| Acrivon Therapeutics, Inc. (ACRV) | Director, 10% owner | 3 | — | — | 3 |
| Climb Bio, Inc. (CLYM) | Director, 10% owner | 3 | — | — | 3 |
| Acumen Pharmaceuticals, Inc. (ABOS) | Director, 10% owner | 1 | — | — | 2 |
+11 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — Shah Rajeev M.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter | Purchase (P): 9,078,529 (derivative) @ $22.03 | EDGAR |
| 2026-09-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 16,250 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 13,750 (derivative) @ $0 | EDGAR |
| 2026-08-26 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Option exercise (M): 1,500 @ $3.74 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Sale (S): 746,500 @ $42.50 · Sale (S): 746,500 @ $42.50 | EDGAR |
| 2026-07-31 | 4 | Inhibikase Therapeutics, Inc. (IKT) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Other (J): 18,030,000 · Other (J): 18,030,000 (derivative) | EDGAR |
| 2026-07-31 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 20,824 @ $9.99 · Purchase (P): 24,944 @ $9.93 | EDGAR |
| 2026-07-28 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 41,319 @ $9.99 | EDGAR |
| 2026-07-23 | 4/A | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 6,522 @ $8.94 | EDGAR |
| 2026-07-23 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 120,582 @ $9.55 · Purchase (P): 84,124 @ $9.93 · Purchase (P): 59,880 @ $9.96 | EDGAR |
| 2026-07-22 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 98,433 @ $27.13 · Purchase (P): 32,987 @ $27.72 · Purchase (P): 21,696 @ $27.96 · Purchase (P): 6,504 @ $29.17 · Purchase (P): 37,723 @ $30 · Purchase (P): 47,250 @ $29.77 | EDGAR |
| 2026-07-22 | 4 | Freenome, Inc. (FRNM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 6,561,711 · Grant/award (A): 970,950 · Grant/award (A): 553,703 · Grant/award (A): 908,103 · Grant/award (A): 367,427 · Grant/award (A): 4,918,411 @ $10 · +1 more | EDGAR |
| 2026-07-21 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Option exercise/expiry (X): 2,100,000 @ $0.00 · Sale (S): 213 @ $19.75 · Option exercise/expiry (X): 2,100,000 (derivative) @ $5 | EDGAR |
| 2026-07-20 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 152,472 @ $8.93 · Purchase (P): 7,882 @ $8.95 | EDGAR |
| 2026-07-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 15,102 @ $8.97 · Purchase (P): 6,552 @ $8.94 | EDGAR |
| 2026-07-01 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 70,284 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 31,000 @ $8.88 · Purchase (P): 1,876 @ $8.98 | EDGAR |
| 2026-06-26 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Sale (S): 389,216 @ $0.35 · Sale (S): 27,695 @ $0.35 | EDGAR |
| 2026-06-18 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 17,340 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Purchase (P): 6,146 @ $24.89 · Purchase (P): 61,523 @ $24.98 | EDGAR |
| 2026-06-16 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Sale (S): 159,119 @ $0.40 · Sale (S): 11,322 @ $0.40 · Sale (S): 120,216 @ $0.39 · Sale (S): 8,554 @ $0.39 · Sale (S): 139,686 @ $0.37 · Sale (S): 9,939 @ $0.37 | EDGAR |
| 2026-06-16 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 391,019 @ $8.57 · Purchase (P): 15,414 @ $8.99 · Purchase (P): 124,893 @ $8.89 | EDGAR |
| 2026-06-15 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Conversion (C): 6,556,740 · Conversion (C): 1,187,881 · Purchase (P): 19,728,353 @ $20 · Purchase (P): 1,460,397 @ $20 · Conversion (C): 642,250 (derivative) · Conversion (C): 160,562 (derivative) · +2 more | EDGAR |
| 2026-06-15 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Grant/award (A): 57,162 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Nkarta, Inc. (NKTX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 20,215 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 479,039 @ $6.91 · Purchase (P): 103 @ $7 · Purchase (P): 548,580 @ $7.91 | EDGAR |
| 2026-06-11 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Sale (S): 345,235 @ $0.37 · Sale (S): 24,565 @ $0.37 · Sale (S): 42,872 @ $0.37 · Sale (S): 3,051 @ $0.37 · Sale (S): 245,066 @ $0.38 · Sale (S): 17,437 @ $0.38 | EDGAR |
| 2026-06-10 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Tyra Biosciences, Inc. (TYRA) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Purchase (P): 3,802 @ $24.97 · Purchase (P): 996 @ $24.94 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-14 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Purchase (P): 6,387 @ $24.90 | EDGAR |
| 2026-05-13 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Purchase (P): 6,510,416 @ $11.52 · Purchase (P): 2,170,138 (derivative) @ $11.52 | EDGAR |
| 2026-05-12 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Sale (S): 351,514 @ $0.71 · Sale (S): 25,012 @ $0.71 · Sale (S): 81,678 @ $0.67 · Sale (S): 5,812 @ $0.67 · Sale (S): 94,432 @ $0.64 · Sale (S): 6,719 @ $0.64 | EDGAR |
| 2026-05-11 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Purchase (P): 7,921 @ $24.34 · Purchase (P): 1,985 @ $24.95 · Purchase (P): 1,483 @ $24.98 · Purchase (P): 14,149 @ $24.47 · Purchase (P): 25,720 @ $25 | EDGAR |
| 2026-05-06 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund IV, L.P., Kolchinsky Peter | Conversion (C): 3,607,846 · Conversion (C): 1,009,052 · Conversion (C): 221,188 · Purchase (P): 2,541,250 @ $18 · Purchase (P): 133,750 @ $18 · Purchase (P): 87,143 @ $24.59 · +9 more | EDGAR |
| 2026-04-29 | 4 | Adicet Bio, Inc. (ACET) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Other (J): 250,000 · Other (J): 250,000 (derivative) | EDGAR |
| 2026-04-29 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter | Grant/award (A): 2,106,000 (derivative) @ $9.50 | EDGAR |
| 2026-04-28 | 4 | Prelude Therapeutics Inc (PRLD) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Other (J): 1,407,000 · Other (J): 1,407,000 (derivative) | EDGAR |
| 2026-04-24 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter | Sale (S): 165,150 @ $15.77 | EDGAR |
| 2026-04-23 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter | Grant/award (A): 3,888,888 @ $1.80 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1619841 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →